Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSTP1 known ✓ | P09211 | 1/20 | 0.51 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.45 |
| ▸ | DRD1 known ✓ | P21728 | 2/20 | 0.41 |
| ▸ | JAK2 known ✓ | O60674 | 1/20 | 0.41 |
| ▸ | DRD2 known ✓ | P14416 | 1/20 | 0.40 |
| ▸ | FTO | Q9C0B1 | 10/20 | 0.69 |
| ▸ | MAPT | P10636 | 3/20 | 0.66 |
| ▸ | HPGD | P15428 | 2/20 | 0.66 |
| ▸ | MEN1 | O00255 | 2/20 | 0.66 |
| ▸ | HTT | P42858 | 2/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.66 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.66 |
| ▸ | RECQL | P46063 | 1/20 | 0.66 |
| ▸ | BLM | P54132 | 1/20 | 0.66 |
| ▸ | SMAD3 | P84022 | 1/20 | 0.66 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.66 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.66 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.66 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30249984 | 0.99 | FTO (0.70) | FTOMAPTHPGDMEN1HTT | |
| SCHEMBL2334255 | 0.99 | FTO (0.70) | FTOMAPTHPGDMEN1HTT | |
| Bromide SCHEMBL6999393 | 0.97 | FTO (0.69) | FTOMAPTHPGDMEN1HTT | |
| Hydrochloric Acid SCHEMBL8542650 | 0.91 | FTO (0.64) | FTOMAPTHPGDMEN1HTT | |
| SCHEMBL29496646 | 0.90 | FTO (0.66) | FTOMAPTHPGDMEN1HTT | |
| SCHEMBL1949992 | 0.90 | FTO (0.66) | FTOMAPTHPGDMEN1HTT | |
| Bromide SCHEMBL7792912 | 0.89 | FTO (0.64) | FTOMAPTHPGDMEN1HTT | |
| SCHEMBL22772907 | 0.87 | FTO (0.69) | FTOMAPTHPGDMEN1HTT | |
| SCHEMBL14498109 | 0.86 | FTO (0.67) | FTOMAPTHPGDMEN1HTT | |
| SCHEMBL337558 | 0.86 | FTO (0.67) | FTOMAPTHPGDMEN1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110643032-B | Eight-arm polyethylene glycol, preparation method, functionalized derivative and modified biologically-relevant substance | 厦门赛诺邦格生物科技股份有限公司 | 2022-01-28 | — | — | CN | claimed |
| CN-110643032-A | Eight-arm polyethylene glycol, preparation method, functionalized derivative and modified biologically-relevant substance | 厦门赛诺邦格生物科技股份有限公司 | 2020-01-03 | — | — | CN | claimed |
| US-7550447-B2 | Method for precipitating nucleic acid with visible carrier | MERCK PATENT GMBH (DE) | 2009-06-23 | — | — | US | claimed |
| US-20070178601-A1 | METHOD FOR PRECIPITATING NUCLEIC ACID WITH VISIBLE CARRIER | EMD BIOSCIENCES, INC. | 2007-08-02 | — | — | US | claimed |
| US-7144713-B1 | Method for precipitating nucleic acid with visible carrier | EMD BIOSCIENCES, INC. (US) | 2006-12-05 | — | — | US | claimed |
| EP-0853680-B1 | METHOD FOR PRECIPITATING NUCLEIC ACID WITH VISIBLE CARRIER | EMD BIOSCIENCES INC (US) | 2004-03-31 | — | — | EP | claimed |
| EP-0853680-A4 | METHOD FOR PRECIPITATING NUCLEIC ACID WITH VISIBLE CARRIER | NOVAGEN INC (US) | 2000-09-13 | — | — | EP | claimed |
| EP-0853680-A1 | METHOD FOR PRECIPITATING NUCLEIC ACID WITH VISIBLE CARRIER | NOVAGEN, INC. (US) | 1998-07-22 | — | — | EP | claimed |
| WO-1997012994-A1 | METHOD FOR PRECIPITATING NUCLEIC ACID WITH VISIBLE CARRIER | NOVAGEN, INC. (US) | 1997-04-10 | — | — | WO | claimed |
| US-11324827-B2 | Multifunctionalized polyethylene glycol derivative and preparation method therefor | XIAMEN SINOPEG BIOTECH CO., LTD. (CN) | 2022-05-10 | — | — | US | disclosed |
| CN-110643032-B | Eight-arm polyethylene glycol, preparation method, functionalized derivative and modified biologically-relevant substance | 厦门赛诺邦格生物科技股份有限公司 | 2022-01-28 | — | — | CN | disclosed |
| US-11214661-B2 | Three-dimensional nanofabrication by patterning of hydrogels | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2022-01-04 | — | — | US | disclosed |
| US-10660969-B2 | Eight-arm polyethylene glycol derivative, production method therefor, and modified bio-related substance thereof | XIAMEN SINOPEG BIOTECH CO., LTD. (CN) | 2020-05-26 | — | — | US | disclosed |
| CN-110643032-A | Eight-arm polyethylene glycol, preparation method, functionalized derivative and modified biologically-relevant substance | 厦门赛诺邦格生物科技股份有限公司 | 2020-01-03 | — | — | CN | disclosed |
| US-5741715-A | FLUORESCENT POLARIZATION IMMUNOASSAY | ROCHE DIAGNOSTIC SYSTEMS, INC. (US) | 1998-04-21 | — | — | US | disclosed |
| WO-1996039180-A1 | IMMUNOGEN PREPARATION WITH HAPTEN | ABBOTT LABORATORIES (US) | 1996-12-12 | — | — | WO | disclosed |
| EP-0745602-A1 | Quinidine immunoassay and reagents | F. HOFFMANN-LA ROCHE AG (CH) | 1996-12-04 | — | — | EP | disclosed |
| US-5489668-A | DERIVATIVES LABELED WITH DETECTABLE FLUORESCEIN MOIETY FOR USE AS TRACERS | ABBOTT LABORATORIES (US) | 1996-02-06 | — | — | US | disclosed |
| EP-0473961-B1 | Immunoassay reagents and method for determining cyclosporine | ABBOTT LAB (US) | 1996-01-03 | — | — | EP | disclosed |
| EP-0473961-A2 | Immunoassay reagents and method for determining cyclosporine | ABBOTT LABORATORIES (US) | 1992-03-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10660969-B2 | Eight-arm polyethylene glycol derivative, production method therefor, and modified bio-related substance thereof | MRPL38, ALG8, COG8 | GSTP1 2113/4885KCNH2 3081/4885DRD1 1230/4885 |
| US-11324827-B2 | Multifunctionalized polyethylene glycol derivative and preparation method therefor | HDGF, F11, F12 | GSTP1 2121/4885KCNH2 4045/4885DRD1 2665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.